该化合物是一种硅醚保护的类固醇衍生物，用作类固醇类药物活性成分合成的医药中间体。其结构包含叔丁基二甲基硅基和三甲基硅基保护基，有助于在类固醇骨架构建过程中实现选择性化学转化。
内容范围: 本页信息面向化学品识别与工业供应、研发、生产场景，不构成疗效宣称、医疗建议或药品使用指导。
(17beta)-3-Oxoestra-4,6-dien-17-yl acetate
医药中间体
(8S,13S,14S,17R)-13-Methyl-17-(2-methyl-1,3-dioxolan-2-yl)-1,2,4,6,7,8,12,13,14,15,16,17-dodecahydrospiro(cyclopenta(a)phenanthrene-3,2'-(1,3)dioxolan)-17-ol
医药中间体
Cyclic 3-(1,2-ethanediylacetale)-estra-5(10),9(11)-diene-3,17-dione
医药中间体
Androsta-4,8-diene-3,17-dione
医药中间体
5-bromo-2-methyl-3-nitropyridine
医药中间体
Benzhydryl (6R,7R)-3-(chloromethyl)-7-[(4-methylbenzoyl)amino]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
医药中间体
(1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid
医药中间体
3-aminoazetidine, 3-boc protected
医药中间体
methyl (4R)-4-[(3R,5S,8S,9S,10S,13R,14S,17R)-3-[tert-butyl(dimethyl)silyl]oxy-10,13-dimethyl-7-trimethylsilyloxy-2,3,4,5,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate
LLDQVINTBNWOHR-VNCOJPLFSA-N
C[C@H](CCC(=O)OC)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C(=C[C@H]4[C@@]3(CC[C@H](C4)O[Si](C)(C)C(C)(C)C)C)O[Si](C)(C)C)C
—